AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23875789 — intervention group
Group type: EXPERIMENTAL
Intervention: Teflon tape technique
Number of subjects: 60
Study 23875789 — intervention group
Group type: EXPERIMENTAL
Intervention: Pull-through technique
Number of subjects: 60
Study 23875789 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioclear matrix technique
Number of subjects: 60
Study 23875789 — intervention group
Group type: COMPARATOR
Intervention: All techniques
Number of subjects: 60
Study 21844885 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI + bevacizumab
Number of subjects: 173
Study 21844885 — intervention group
Group type: EXPERIMENTAL
Intervention: XELIRI + bevacizumab
Number of subjects: 173
Study 19608110 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional photos
Number of subjects: 74
Study 19608110 — intervention group
Group type: COMPARATOR
Intervention: Calm photos
Number of subjects: 74
Study 19608110 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with significant differential effects in pupillary dilation
Number of subjects: 74
Study 19608110 — intervention group
Group type: EXPERIMENTAL
Intervention: Varying probability of observing future images
Number of subjects: 74
Study 17720628 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 0
Study 17720628 — intervention group
Group type: EXPERIMENTAL
Intervention: Paradoxical therapy
Number of subjects: 0
Study 15165412 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental test (stimulated subjects)
Number of subjects: 26
Study 15165412 — intervention group
Group type: COMPARATOR
Intervention: Control test (no humans present)
Number of subjects: 26
Study 15165412 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulated subjects' event‐related potentials
Number of subjects: 26
Study 12126525 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone group (14 cases) treated by methimazole 15 approximately 30 mg/d, propranolol 15 approximately 30 mg/d, and prednisone 30 mg/d
Number of subjects: 24
Study 12126525 — intervention group
Group type: COMPARATOR
Intervention: Traditional antithyroid group (10 cases) treated by methimazole 15 approximately 30 mg/d and propranolol 15 approximately 30 mg/d
Number of subjects: 24
Study 9533674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochrane Collaboration systematic reviews
Number of subjects: 0
Study 9533674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochrane Collaborative Review Group for Headache
Number of subjects: 0
Study 9533674 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorporating evidence into treatment guidelines
Number of subjects: 0
Study 7491854 — intervention group
Group type: EXPERIMENTAL
Intervention: GyneFix (frameless, flexible IUD)
Number of subjects: 10000
Study 7491854 — intervention group
Group type: EXPERIMENTAL
Intervention: GyneFix
Number of subjects: 10000
Study 28885671 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 horizontal muscle surgery (group 1)
Number of subjects: 37
Study 28885671 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 oblique muscle surgery (group 2)
Number of subjects: 37
Study 28885671 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 horizontal muscle surgeries (group 3)
Number of subjects: 37
Study 28885671 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 horizontal and 1 oblique muscle surgery (group 4)
Number of subjects: 37
Study 27607876 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (14-week supervised home-based stationary cycling program)
Number of subjects: 172
Study 27607876 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 172
Study 25645325 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (Norditropin(®) SimpleXx)
Number of subjects: 9
Study 25645325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 25645325 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline (Turner syndrome)
Number of subjects: 9
Study 25645325 — intervention group
Group type: COMPARATOR
Intervention: Controls (age-matched females)
Number of subjects: 9
Study 25645325 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 9
Study 23013207 — intervention group
Group type: EXPERIMENTAL
Intervention: ETN 50 mg BIW for 12 weeks followed by QW for 12 weeks (BIW/QW group)
Number of subjects: 72
Study 23013207 — intervention group
Group type: EXPERIMENTAL
Intervention: ETN 50 mg QW for 24 weeks (QW/QW group)
Number of subjects: 72
Study 22052313 — intervention group
Group type: EXPERIMENTAL
Intervention: Hair Stimulating Complex (HSC)
Number of subjects: 26
Study 22052313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 19371492 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing with personalized feedback (MI)
Number of subjects: 215
Study 19371492 — intervention group
Group type: COMPARATOR
Intervention: Personalized feedback only (Control)
Number of subjects: 215
Study 19371492 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (MI and Control)
Number of subjects: 215
Study 16941666 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical teaching (31%)
Number of subjects: 177
Study 16941666 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational teaching (27%)
Number of subjects: 177
Study 16941666 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive counseling (33%)
Number of subjects: 177
Study 16941666 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial counseling (9%)
Number of subjects: 177
Study 16941666 — intervention group
Group type: COMPARATOR
Intervention: Counseling model sessions
Number of subjects: 177
Study 15203476 — intervention group
Group type: EXPERIMENTAL
Intervention: Literature and medicine elective course (8 sessions)
Number of subjects: 22
Study 15203476 — intervention group
Group type: COMPARATOR
Intervention: Wait-list group (control)
Number of subjects: 22
Study 11307260 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl
Number of subjects: 100
Study 11307260 — intervention group
Group type: COMPARATOR
Intervention: Initial-saline
Number of subjects: 100
Study 11307260 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% NaOCl
Number of subjects: 100
Study 9709280 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic screening
Number of subjects: 160000
Study 9709280 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular screening of 10,000 women aged 40-49
Number of subjects: 160000
Study 8513844 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of the tablet to the gingiva
Number of subjects: 10
Study 8513844 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of the tablet to the palate
Number of subjects: 10
Study 8513844 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of the tablet to the cheek
Number of subjects: 10
Study 8513844 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of the tablet to the cheek in comatose intubated patients
Number of subjects: 10
Study 3552302 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine and isosorbide dinitrate
Number of subjects: 642
Study 3552302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 642
Study 3552302 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 642
Study 30356057 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with a standardised anaesthetic regimen (ACU)
Number of subjects: 75
Study 30356057 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure (APU)
Number of subjects: 75
Study 30356057 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard anaesthesia alone, CON)
Number of subjects: 75
Study 30356057 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (ACU) and Acupressure (APU)
Number of subjects: 75
Study 27296848 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional third dose (Fx017M)
Number of subjects: 46
Study 27296848 — intervention group
Group type: COMPARATOR
Intervention: Full-dose regimen (012M)
Number of subjects: 46
Study 24754142 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10 mg orally daily for 14 days)
Number of subjects: 88
Study 24754142 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral)
Number of subjects: 88
Study 22261830 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary counseling/testing (VC/T) with drug treatment referral
Number of subjects: 1030
Study 22261830 — intervention group
Group type: COMPARATOR
Intervention: Voluntary counseling/testing (VC/T), referral, and brief motivational intervention (B-MI)
Number of subjects: 1030
Study 19779855 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational enhancement intervention
Number of subjects: 143
Study 19779855 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 143
Study 18502603 — intervention group
Group type: EXPERIMENTAL
Intervention: GABI scale
Number of subjects: 106
Study 18502603 — intervention group
Group type: COMPARATOR
Intervention: Standard scales (ADL, IADL, AGGIR, Barthel)
Number of subjects: 106
Study 15825070 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab maintenance treatment (5 mg/kg every 8 weeks)
Number of subjects: 282
Study 15825070 — intervention group
Group type: COMPARATOR
Intervention: Placebo maintenance
Number of subjects: 282
Study 12231656 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mmHg pressure step protocol
Number of subjects: 18
Study 12231656 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mmHg pressure step protocol
Number of subjects: 18
Study 12231656 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mmHg pressure step after transient venous decongestion
Number of subjects: 18
Study 12231656 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mmHg pressure step after transient venous decongestion
Number of subjects: 18
Study 12231656 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mmHg pressure step after transient deflation
Number of subjects: 18
Study 12231656 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mmHg pressure step after transient deflation
Number of subjects: 18
Study 12231656 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient pressure reduction
Number of subjects: 18
Study 10512939 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free laparoscopic hernia repair (LHR)
Number of subjects: 105
Study 10512939 — intervention group
Group type: COMPARATOR
Intervention: Open hernia repair (OHR)
Number of subjects: 105
Study 8770666 — intervention group
Group type: EXPERIMENTAL
Intervention: SIN-1 (linsidomine chlorhydrate)
Number of subjects: 40
Study 8770666 — intervention group
Group type: EXPERIMENTAL
Intervention: SIN-1 plus Urapidil
Number of subjects: 40
Study 8770666 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin E1 (PGE1)
Number of subjects: 40
Study 1952266 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine (MC) subcutaneous injections
Number of subjects: 31
Study 1952266 — intervention group
Group type: COMPARATOR
Intervention: Atropine (AT) subcutaneous injections
Number of subjects: 31
Study 1952266 — intervention group
Group type: COMPARATOR
Intervention: Multi-electrolyte solution (MES) injections
Number of subjects: 31
Study 1952266 — intervention group
Group type: COMPARATOR
Intervention: AT-containing lotion
Number of subjects: 31
Study 1952266 — intervention group
Group type: EXPERIMENTAL
Intervention: MC-containing lotion
Number of subjects: 31
Study 1952266 — intervention group
Group type: EXPERIMENTAL
Intervention: MES solution
Number of subjects: 31
Study 1952266 — intervention group
Group type: EXPERIMENTAL
Intervention: MES solution with MC addition
Number of subjects: 31
Study 1952266 — intervention group
Group type: COMPARATOR
Intervention: MES solution with AT addition
Number of subjects: 31
Study 7134858 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection combined with conversion to an end‐to‐end anastomosis (Scott)
Number of subjects: 16
Study 7134858 — intervention group
Group type: COMPARATOR
Intervention: Simple resection of the elongated segment of the shunt
Number of subjects: 16
Study 31910459 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Borderline Personality Disorder (BPD)
Number of subjects: 37
Study 31910459 — intervention group
Group type: COMPARATOR
Intervention: Patients with depressive disorder
Number of subjects: 37
Study 30306831 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment for 8 weeks
Number of subjects: 25
Study 30306831 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment for 8 weeks (responders)
Number of subjects: 25
Study 29084595 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared care model involving replacement of two routine specialist follow‐up visits with PCP visits, provision of a tailored survivorship care plan, and a survivorship booklet and DVD for CRC survivors.
Number of subjects: 0
Study 29084595 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 0
Study 25800376 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment of hip fractures in patients with Parkinson's disease
Number of subjects: 141
Study 25800376 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment of hip fractures in patients without Parkinson's disease (Control)
Number of subjects: 141
Study 25800376 — intervention group
Group type: EXPERIMENTAL
Intervention: Reoperation for displaced and nondisplaced fractures in patients with Parkinson's disease
Number of subjects: 141
Study 25800376 — intervention group
Group type: COMPARATOR
Intervention: Reoperation for displaced and nondisplaced fractures in patients without Parkinson's disease (Control)
Number of subjects: 141
Study 25800376 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation for nondisplaced femoral neck fractures in patients with Parkinson's disease
Number of subjects: 141
Study 25800376 — intervention group
Group type: COMPARATOR
Intervention: Internal fixation for nondisplaced femoral neck fractures in patients without Parkinson's disease (Control)
Number of subjects: 141
Study 25800376 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty for displaced femoral neck fractures in patients with Parkinson's disease
Number of subjects: 141
Study 25800376 — intervention group
Group type: COMPARATOR
Intervention: Hemiarthroplasty for displaced femoral neck fractures in patients without Parkinson's disease (Control)
Number of subjects: 141
Study 25800376 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty through an anterolateral approach
Number of subjects: 141
Study 25800376 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty through a posterior approach
Number of subjects: 141
Study 24898622 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ivermectin (1% applied to affected skin, 400 μg/kg, repeated once the following week)
Number of subjects: 340
Study 24898622 — intervention group
Group type: COMPARATOR
Intervention: Crotamiton cream 10% (applied twice daily for five consecutive days)
Number of subjects: 340
Study 21696902 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate (n=20 patients)
Number of subjects: 40
Study 21696902 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (n=20 patients; control group)
Number of subjects: 40
Study 19390585 — intervention group
Group type: EXPERIMENTAL
Intervention: AMA-1/AS01B (50 microg/0.5 mL)
Number of subjects: 30
Study 19390585 — intervention group
Group type: EXPERIMENTAL
Intervention: AMA-1/AS02A (50 microg/0.5 mL)
Number of subjects: 30
Study 19390585 — intervention group
Group type: EXPERIMENTAL
Intervention: AMA-1/AS01B (10 microg/0.5 mL)
Number of subjects: 30
Study 19390585 — intervention group
Group type: EXPERIMENTAL
Intervention: AMA-1/AS02A
Number of subjects: 30
Study 19390585 — intervention group
Group type: COMPARATOR
Intervention: Control (malaria challenge with P. falciparum-infected mosquitoes)
Number of subjects: 30
Study 17531696 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaxial phacoemulsification
Number of subjects: 30
Study 17531696 — intervention group
Group type: COMPARATOR
Intervention: Microincision cataract surgery (MICS)
Number of subjects: 30
Study 15298068 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingually administered cannabis extracts containing approximately equal concentrations of delta9-THC and cannabidiol
Number of subjects: 0
Study 15298068 — intervention group
Group type: COMPARATOR
Intervention: Delta9-tetrahydrocannabinol (delta9-THC)
Number of subjects: 0
Study 11313175 — intervention group
Group type: EXPERIMENTAL
Intervention: CAELYX (50 mg/m² by a 1 h intravenous infusion every 4 weeks)
Number of subjects: 94
Study 11313175 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (75 mg/m² by an intravenous bolus every 3 weeks)
Number of subjects: 94
Study 9392331 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic screening every 18 months using two-view mammography
Number of subjects: 11724
Study 9392331 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic screening with conservative estimate removing tumors detected at first screen of control group
Number of subjects: 11724
Study 9392331 — intervention group
Group type: COMPARATOR
Intervention: Control group (not invited to screening until the fifth screen)
Number of subjects: 11724
Study 8179235 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple item elimination diet
Number of subjects: 26
Study 8179235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 3131387 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure FSH (A1)
Number of subjects: 16
Study 3131387 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of LHRH agonist and pure FSH (A2)
Number of subjects: 16
Study 3131387 — intervention group
Group type: COMPARATOR
Intervention: Control group (B)
Number of subjects: 16
Study 31914967 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based, gender-sensitive and culturally adapted brief counselling intervention (SIRIAN program)
Number of subjects: 0
Study 31914967 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 0
Study 31928038 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation of positive emotions
Number of subjects: 0
Study 31928038 — intervention group
Group type: COMPARATOR
Intervention: Negative emotions
Number of subjects: 0
Study 31928038 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress
Number of subjects: 0
Study 31928038 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 0
Study 31928038 — intervention group
Group type: EXPERIMENTAL
Intervention: Orosensory stimulation via sweet taste
Number of subjects: 0
Study 31928038 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music
Number of subjects: 0
Study 31928038 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0
Study 28124506 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide up to 1.8 mg s.c. once daily
Number of subjects: 95
Study 28124506 — intervention group
Group type: COMPARATOR
Intervention: Metformin up to 1,000 mg twice daily
Number of subjects: 95
Study 25922119 — intervention group
Group type: EXPERIMENTAL
Intervention: MLP using 16 clinical variables
Number of subjects: 1924
Study 24069472 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole treatment with weekly evaluations
Number of subjects: 162
Study 24069472 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole treatment with twice-weekly evaluations
Number of subjects: 162
Study 24069472 — intervention group
Group type: COMPARATOR
Intervention: Benznidazole treatment with historical controls
Number of subjects: 162
Study 24069472 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole treatment with prospective patients
Number of subjects: 162
Study 24069472 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole treatment
Number of subjects: 162
Study 21848444 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive-counselling group (n = 61)
Number of subjects: 120
Study 21848444 — intervention group
Group type: COMPARATOR
Intervention: Brief-counselling group (n = 59)
Number of subjects: 120
Study 20166438 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 40, 80, and 120 mg intramuscular tramadol hydrochloride injection
Number of subjects: 0
Study 17266689 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg per day for 4 weeks followed by peg‐IFN 1.0 mug/kg/wk for 24 weeks (Group B)
Number of subjects: 63
Study 17266689 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks followed by peg‐IFN 1.0 mug/kg/wk for 24 weeks (Group A)
Number of subjects: 63
Study 15519189 — intervention group
Group type: EXPERIMENTAL
Intervention: PDE III inhibitor (PDE III‐I)
Number of subjects: 80
Study 15519189 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 80
Study 15519189 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine hydrochloride
Number of subjects: 80
Study 15519189 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 80
Study 12521457 — intervention group
Group type: EXPERIMENTAL
Intervention: Push method
Number of subjects: 108
Study 12521457 — intervention group
Group type: COMPARATOR
Intervention: Pull (reverse breech) method
Number of subjects: 108
Study 9890717 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIa (NovoSeven) at doses of 5, 10, 20, 40, 80, 120, 160, 240, or 320 microg/kg
Number of subjects: 28
Study 9890717 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 28
Study 9890717 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIa (NovoSeven)
Number of subjects: 28
Study 8017663 — intervention group
Group type: COMPARATOR
Intervention: Volume-Controlled Ventilation (VC)
Number of subjects: 9
Study 8017663 — intervention group
Group type: COMPARATOR
Intervention: Pressure-Controlled Ventilation (PCV) with conventional ratio (I:E 1:2; PC 1/2)
Number of subjects: 9
Study 8017663 — intervention group
Group type: COMPARATOR
Intervention: Pressure-Controlled Inverse Ratio Ventilation (PCIRV) (I:E 2:1 and 3:1; PC 2/1 and PC 3/1)
Number of subjects: 9
Study 8017663 — intervention group
Group type: EXPERIMENTAL
Intervention: PC 2/1
Number of subjects: 9
Study 8017663 — intervention group
Group type: EXPERIMENTAL
Intervention: PC 3/1
Number of subjects: 9
Study 2810454 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine
Number of subjects: 0
Study 2810454 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 0